A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor

Trial Profile

A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2015

At a glance

  • Drugs Vintafolide (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 14 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 11 Mar 2014 Planned End Date changed from 1 Jun 2015 to 1 Mar 2015 as reported by ClinicalTrial.gov record.
    • 11 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top